Topic: Orencia
LONDON (Reuters) - Britain's health cost watchdog has changed tack and recommended that rheumatoid arthritis patients should have more options if they do not respond adequately to treatment with a so-called TNF inhibitor drug. The National Institute for Health and Clinical Excellence ...
